%PDF-1.4
%
38 0 obj
<>
endobj
35 0 obj
<>
endobj
88 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T12:32:01Z
2024-03-28T17:32:07-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T17:32:07-07:00
application/pdf
Heather
2002-508.april
uuid:0d9cb59a-1dd2-11b2-0a00-6909277d8900
uuid:0d9cb59c-1dd2-11b2-0a00-d30000000000
endstream
endobj
24 0 obj
<>
endobj
25 0 obj
<>
endobj
39 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
102 0 obj
[106 0 R]
endobj
103 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc -0.0061 Tw 9.7 0 0 10 54 712.2563 Tm
(scarce. Bizzaro, )Tj
/T1_1 1 Tf
(et al)Tj
/T1_0 1 Tf
0.00079 Tc 0 Tw 6.3 0 0 6.5 134.8728 715.5564 Tm
(15)Tj
-0.00011 Tc -0.0061 Tw 9.7 0 0 10 143.5436 712.2563 Tm
[(describe negative anti-CCP)-207.1 (results in 3)]TJ
-0.0363 Tw -9.2313 -1.2 Td
[(tested JIA)-158.9 (patients \(subtype unknown\). Recently)64.8 (, )54.8 (A)74 (vcin, )]TJ
/T1_1 1 Tf
22.379 0 Td
(et al)Tj
/T1_0 1 Tf
0.00079 Tc 0 Tw 6.3 0 0 6.5 287.695 703.5564 Tm
(22)Tj
-0.00011 Tc 0.28149 Tw 9.7 0 0 10 54 688.2563 Tm
[(described anti-CCP)-494.7 (positivity in 2 out of 108 tested JIA)]TJ
0.28931 Tw 0 -1.2 TD
(patients \(oligoarticular and polyarticular IgM-RF negative)Tj
0.0358 Tw T*
[(patients\). One polyarticular IgM-RF positive JIA)-231 (patient test-)]TJ
-0.0287 Tw T*
[(ed negative. )54.9 (Although their cut-of)17.7 (f value, using the same com-)]TJ
0.0287 Tw T*
[(mercial anti-CCP)-242 (test we used, was 70 units, our results were)]TJ
0.0415 Tw T*
[(very similar)54.8 (. In our study only one patient with a value of 60)]TJ
0.1521 Tw T*
[(units \(T)69.7 (able 2\) was considered anti-CCP)-365.4 (positive, while all)]TJ
0.0354 Tw T*
[(others had values above 70 units. )17.7 (Therefore our results are in)]TJ
0.1239 Tw T*
[(agreement with the results published by )54.9 (A)74 (vcin and cowork-)]TJ
-0.0002 Tc 0 Tw T*
(ers)Tj
0.00079 Tc 6.3 0 0 6.5 65.3056 583.5564 Tm
(22)Tj
-0.00011 Tc 0.01221 Tw 9.7 0 0 10 74.1537 580.2563 Tm
[(and indicate that anti-CCP)-225.4 (antibodies are present in only)]TJ
0.02499 Tw -2.0777 -1.2 Td
[(a subset of JIA)-220.2 (patients. )]TJ
0.1127 Tw 1.2371 -1.2 Td
(Because of the very high specificity of this autoantibody)Tj
-0.0322 Tw -1.2371 -1.2 Td
[(system for adult RA)-163 (\(more than 97%\))]TJ
0 Tc 0 Tw 6.3 0 0 6.5 198.1199 547.5564 Tm
(8)Tj
-0.00011 Tc -0.0322 Tw 9.7 0 0 10 201.2724 544.2563 Tm
(, it seems likely that this)Tj
0.0804 Tw -15.1827 -1.2 Td
[(subset includes JIA)-275.5 (patients who are developing a pattern of)]TJ
0.12219 Tw T*
[(involvement like that of adult RA. )17.7 (The observation that the)]TJ
0.18851 Tw T*
[(titer values in the anti-CCP)-401.7 (positive JIA)-383.7 (patients generally)]TJ
0.10091 Tw T*
[(were lower than those observed in adults with RA)-296 (is in line)]TJ
0.22211 Tw T*
(with this assumption of a developing disease. Longer fol-)Tj
0.09151 Tw T*
[(lowup of this group of JIA)-286.7 (patients will provide a definitive)]TJ
0.2374 Tw T*
[(answer as to whether anti-CCP)-450.6 (antibodies can predict the)]TJ
0.02499 Tw T*
(development of an adult RA-like disease pattern in JIA. )Tj
0.0956 Tw 1.2371 -1.2 Td
[(It is known that IgM-RF positive JIA)-290.8 (often has a disease)]TJ
0.0228 Tw -1.2371 -1.2 Td
[(course similar to RA)-218 (in adults)]TJ
0 Tc 0 Tw 6.3 0 0 6.5 170.6737 427.5564 Tm
(6)Tj
-0.00011 Tc 0.0228 Tw 9.7 0 0 10 173.8262 424.2564 Tm
(. Our study confirms this simi-)Tj
-0.0002 Tc 0 Tw -12.3532 -1.2 Td
[(larity)64.7 (.)]TJ
-0.00011 Tc -0.0368 Tw 1.2371 -1.2 Td
[(Although a role for anti-CCP)-176.3 (in RA)-158.3 (has been suggested, the)]TJ
0.061 Tw -1.2371 -1.2 Td
[(significance of anti-CCP)-274.2 (in the disease pathogenesis remains)]TJ
0 Tw T*
(unclear)Tj
0.00079 Tc 6.3 0 0 6.5 82.5388 379.5564 Tm
(23)Tj
-0.00011 Tc -0.01871 Tw 9.7 0 0 10 88.8437 376.2564 Tm
[(. )54.8 (All IgM-RF positive JIA)-176.5 (patients had clinical arthri-)]TJ
0.1806 Tw -3.5921 -1.2 Td
(tis and radiological damage, and almost all were anti-CCP)Tj
0.0231 Tw T*
[(positive. )17.7 (These results confirm previous studies in adult early)]TJ
-0.0023 Tw T*
[(RA)-192.8 (that both IgM-RF and anti-CCP)-210.9 (antibodies can predict the)]TJ
0.0829 Tw T*
(development of a more severe destructive disease course)Tj
0.0004 Tc 0 Tw 6.3 0 0 6.5 279.6496 331.5564 Tm
[(1)56.8 (1-13)]TJ
-0.00011 Tc 0.0188 Tw 9.7 0 0 10 54 316.2564 Tm
(and that their simultaneous presence may be an indication for)Tj
0.02499 Tw T*
(earlier immunosuppressive treatment)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 198.3062 307.5564 Tm
(24)Tj
0 Tc 9.7 0 0 10 204.6112 304.2564 Tm
(. )Tj
-0.00011 Tc 0.2175 Tw -14.2898 -1.2 Td
[(W)79.9 (e have shown that anti-CCP)-430.7 (antibodies can be found)]TJ
0.03101 Tw -1.2371 -1.2 Td
(incidentally in the serum of children with several subtypes of)Tj
-0.0029 Tw T*
(JIA, but that they are commonly present in polyarticular IgM-)Tj
0.0829 Tw T*
[(RF positive JIA)-278.1 (patients. Further followup studies will more)]TJ
0.061 Tw T*
[(firmly establish whether the presence of anti-CCP)-274.2 (antibodies)]TJ
0.099 Tw T*
[(in JIA)-294.1 (patients predicts the development of a disease course)]TJ
0.1972 Tw T*
[(like adult RA)-392.4 (and selects JIA)-392.4 (patients with a more severe)]TJ
0.02499 Tw T*
(destructive disease course. )Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.07091 Tw 7.76 0 0 8 54 174.2564 Tm
[(W)79.9 (e thank Rob van der Stadt \(clinical chemist\) for his contribution and \
sup-)]TJ
0 Tw 0 -1.25 TD
(port. )Tj
/T1_2 1 Tf
9.7 0 0 10 54 140.2564 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 130.2564 Tm
[(1.)-875.1 (W)79.9 (oo P)110.7 (,)-0.1 ( )17.7 (W)79.9 (edderburn LR: Juvenile chronic arthritis. Lancet)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1998;351:969-73.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Petty RE, Southwood )17.7 (TR, Baum J. Revision of the proposed)]TJ
1.675 -1.25 Td
(classification criteria for juvenile idiopathic arthritis: Durban, 1997.\
)Tj
T*
(J Rheumatol 1998;25:1991-4.)Tj
31.325 78.0343 Td
[(3.)-875.1 (Cassidy JT)73.9 (, Petty RE. )17.7 (T)69.9 (extbook of pediatric rheumatology)64.8 (. 4th ed.)]TJ
0 Tc 1.675 -1.25 Td
[(Philadelphia: )17.8 (W)91.9 (.B. Saunders Company; 2001:254-5, 260-2.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Andersson G\212re B, Fasth )54.8 (A. )17.7 (The natural history of juvenile chronic)]TJ
1.675 -1.25 Td
[(arthritis: )54.8 (A)-220.1 (population based cohort study)64.8 (. I. Onset and disease)]TJ
T*
(process. J Rheumatol 1995;22:295-307.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Prieur )54.8 (AM: Juvenile \(chronic\) arthritis is not juvenile rheumatoid)]TJ
1.675 -1.25 Td
(arthritis. Rev Rhum 1996;63:1-4.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Cassidy JT)73.9 (, Petty RE. )17.7 (T)69.9 (extbook of pediatric rheumatology)64.8 (. 4th)]TJ
1.675 -1.25 Td
[(edition Philadelphia: )17.7 (W)91.9 (.)-0.1 (B. Saunders Company; 2001:233-5.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Smolen JS. Rheumatoid arthritis. In: van )17.7 (V)110.8 (enrooij )17.7 (WJ, Maini RN,)]TJ
1.675 -1.25 Td
[(editors. Manual of biological markers. )54.8 (Amsterdam: Kluwer)]TJ
T*
(Academic Publishers 1996: C1.1;1-18.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (V)110.8 (an Boekel MAM, )17.7 (V)128.9 (ossenaar ER, van den Hoogen FHJ, van)]TJ
1.675 -1.25 Td
[(V)110.8 (enrooij )17.7 (WJ. )54.8 (Autoantibody systems in rheumatoid arthritis:)]TJ
T*
[(specificity)64.8 (, sensitivity and diagnostic value. )54.8 (Arthritis Res)]TJ
0 Tc 0 Tw T*
(2002;4:87-93.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Schellekens GA, De Jong BA)79.7 (W)91.9 (,)-0.1 ( )17.7 (V)110.8 (an den Hoogen FHJ, )17.7 (V)110.8 (an de)]TJ
1.675 -1.25 Td
[(Putte LBA, )17.7 (V)110.8 (an )17.7 (V)110.8 (enrooij )17.7 (WJ. Citrulline is an essential constituent)]TJ
T*
(of antigenic determinants recognized by rheumatoid arthritis)Tj
T*
(specific antigens. J Clin Invest 1998;101:273-81.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Schellekens GA, )17.7 (V)59.8 (isser H, De Jong BA)79.7 (W)91.8 (, et al. )17.7 (The diagnostic)]TJ
2.175 -1.25 Td
(properties of rheumatoid arthritis antibodies recognizing a cyclic)Tj
T*
[(citrullinated peptide. )54.8 (Arthritis Rheum 2000;43:155-63.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Kroot EJA, De Jong BA)79.7 (W)91.8 (,)-0.1 ( )17.7 (V)110.8 (an Leeuwen MA, et al. )17.7 (The prognostic)]TJ
2.1381 -1.25 Td
(value of anti-cyclic citrullinated peptide antibody in patients with)Tj
T*
[(recent-onset rheumatoid arthritis. )54.8 (Arthritis Rheum 2000;43:1831-5.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (V)59.8 (isser H, Le Cessie S, )17.7 (V)128.9 (os K, Breedveld FC, Hazes JMW)91.7 (. How to)]TJ
2.175 -1.25 Td
[(diagnose rheumatoid arthritis early)64.8 (. )54.8 (Arthritis Rheum 2002;)]TJ
0 Tc 0 Tw T*
(46:357-65.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (V)110.8 (an Jaarsveld CHM, )17.7 (T)69.9 (er Bor)17.7 (g EJ, Jacobs JWG, et al. )17.7 (The)]TJ
2.175 -1.25 Td
[(prognostic value of the antiperinuclear factor)39.7 (, anti-citrullinated)]TJ
T*
(peptide antibodies and rheumatoid factor in early rheumatoid)Tj
T*
(arthritis. Clin Exp Rheumatol 1999;17:689-97.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Otten HG, Daha MR, de Rooij HH, Breedveld FC. Quantitative)]TJ
2.175 -1.25 Td
(detection of class-specific rheumatoid factors using mouse)Tj
T*
(monoclonal antibodies and the biotin/streptavidin enhancement)Tj
T*
(system. Br J Rheumatol 1989;28:310-6.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Bizzaro N, Mazzanti G, )17.7 (T)69.9 (onutti E, )17.7 (V)59.8 (illalta D, )17.7 (T)69.9 (ozzoli R. Diagnostic)]TJ
2.175 -1.25 Td
(accuracy of the anti-citrulline antibody assay for rheumatoid)Tj
T*
(arthritis. Clin Chem 2001;47:1089-93.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Gabay C, Prieur )54.8 (AM, Meyer O. Occurrence of antiperinuclear)39.7 (,)]TJ
2.175 -1.25 Td
[(antikeratin, and anti-RA)-220.2 (33 antibodies in juvenile chronic arthritis.)]TJ
0 Tc T*
(Ann Rheum Dis 1993;52:785-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (Nesher G, Moore )17.7 (TL, Grisanti MW)91.7 (, El-Najdawi E, Osborn )17.7 (TG.)]TJ
2.175 -1.25 Td
[(Antiperinuclear factor in juvenile rheumatoid arthritis. )54.8 (Ann Rheum)]TJ
T*
(Dis 1992;51:350-2.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Abreu I, Melo Gomes JA. )54.8 (Antikeratin antibodies in chronic arthritis)]TJ
2.175 -1.25 Td
(of childhood [letter]. Clin Exp Rheumatol 1998;16:516-7.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Hromadnikova I, )17.7 (V)110.8 (avrincova P)110.7 (, Stechova K, Hridelova D. )]TJ
2.175 -1.25 Td
(Anti-keratin antibodies in patients with juvenile idiopathic arthritis.)Tj
T*
(Clin Exp Rheumatol 2001;19:470-3.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Essen R von, )36.8 (Ylijoki H, Savolainen )54.8 (A, Haapasaari J, Oksala U.)]TJ
2.175 -1.25 Td
[(Antiperinuclear factor in chronic juvenile arthritis \(letter\). )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 1992;51:1264-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Pelkonen P)110.7 (, Kurki P)110.7 (.)-0.1 ( )54.8 (Antibodies to stratum corneum in juvenile)]TJ
2.175 -1.25 Td
[(chronic arthritis. Clin Exp Rheumatol 1993; Suppl 1)36.8 (1:S-73.)]TJ
-2.175 -1.25 Td
[(22.)-875.1 (A)73.9 (vcin )17.7 (T)74 (, Cimaz R, Falcini F)79.7 (, et al. Prevalence and clinical)]TJ
2.175 -1.25 Td
(significance of anti-cyclic citrullinated peptide antibodies in)Tj
T*
[(juvenile idiopathic arthritis. )54.8 (Ann Rheum Dis 2002; 61:608-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Reparon-Schuijt, van Esch )17.7 (WJE, van Kooten C, et al. Secretion of)]TJ
2.175 -1.25 Td
(anti-citrulline-containing peptide antibody by B lymphocytes in)Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 2001;44:41-7. )]TJ
-2.175 -1.25 Td
[(24.)-875.1 (O\325Dell JR. )17.7 (T)35 (reating rheumatoid arthritis early: a window of)]TJ
2.175 -1.25 Td
[(opportunity? )54.8 (Arthritis Rheum 2002;46:283-5.)]TJ
ET
0 0 0 0 scn
440 777 117 -27 re
f*
BT
0 0 0 1 scn
/T1_3 1 Tf
0 Tw 20.37 0 0 21 441 760.6089 Tm
(\002\003\003\002\004\005\003\006\004")Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:4)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(828)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
53 0 obj
<>
endobj
42 0 obj
<>
endobj
15 0 obj
<>
endobj
43 0 obj
<>
endobj
79 0 obj
<>
endobj
93 0 obj
<>
endobj
45 0 obj
<>
endobj
47 0 obj
<>
endobj
44 0 obj
<>stream
H\Ok0:vY5#K]PFq՛I?dqⰘ9MK|Ωes
9
ryڎa6E<-sieq\{<q14_ۇ0?;BrZN!l,5f\c8vJ[>klbKPB
tzk еb+Rغ8@ntt04{f-%o[ByB4 K 㦄(HX#1By}b_= گԾ3.k 8'_sRSsߣ?*%O`0?3ٞS*L*frӌo% R#
endstream
endobj
46 0 obj
<>stream
H\kPh.NJx}@zYAA-bD.P HPBI1*H@$Yu]+v]]gZ=993sC0?doâtQNZxC8C1ypqC?,<\qi;
]VVsU-:ml>DTZ:(!h΅-acyaا4l3;]30y:vi贙E鋷!=Yp <^Kd/pˊ]~npM*g=O"O\C-akYro#CXׅwh) 8ݣЋt2
A
NшȰ"ow
{1qENҁvEz AoXVGאC~2Ƚp'AO] @D
5-pvG#/n;,|h]Нqipl|~1nK5i4dNSc盆ac>b7/o
p5Lܟbkiiɞd4
p-ޔKlbBkvm!a;]-Q_(1SfIkzѶPa#0lD G(N{qI*$o_8=HyW.}7UUZm9U./&E[h֑uPuFV(K"u&_ӬUCJ]m~AbUH+5ņbM{hg!~ϳX+y8IԧH;RU(8
Ꞇ٫yfUu?&ZȥcamyƨmͺVQ}f٧7ˁlY#9N$2! .m%q*E"%RgT(䳢)f뫦Ƌ+
vq&-NB% q,tX)L{" *DM= YúiC\aPۈ?ؿfmC`w-ɜ8e5E9AadX]4":hʽ
1w;;fŘ6d!Y8<5)>[#~C9-.ETUGN
5pS|/jP!W)k4z0t .U/3Of&Leed\Rr.QffʥʒR$lCkecFURQ[\TURTsH\M_O7?9Lې~G&etj xnRѫ~4ݴi2u:
BeJ(fE-!Րҿ ?%*U@ڮs+J33-Ӭ%bV *T0
rH]T$g3#E>`Uh ?ߦnwmsNY8ܩOrbc ~LMԧ_]]8v+.drCj]{OY-)0ZqCdWpt:Ș&A<jsP``O
9'%v_jY=;6~Ux̼p5/h_ojѭ^}94GO
&bV<6h%SYbتzs2AS>Ad,p$?s$'k4Дv^$yђXR4<ZbXSZO
HƦu]d͑G:OjJUAeėWIZVqci4g;p9dJ*dTR*B_;YpVϰhTŢ*j
j%)σpǂ{9'ZOMgnHOϦȵXkʽ+jLgSSSS
ܣyt]C(Ax]BKI͇O}% J<6/+t?L`_t{\W}
؛u!6'мz#l
frPNuuD||?Kd{dYkbkߦ*X)k"[Դ}zo
"l+sD~
8Q) ӭCHVA˅XFcӻ5n8]>ζPIWtd,2gZA.Ds_1vڊHs=kiѱqltN,z^Pl+?ʰy]=Yg?bنB73d[2*DM{h9UJQN:*թ֠UKGR|Ta: A#ammu>BC|sohX2R"m|>y=_XUQRKj gcXWKw3!ɄǦS`gLOchXQ?'GԬ*Sr\$sa᷿8g;t[/{